Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Interest & Investment Income (2023 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Interest & Investment Income for 3 consecutive years, with -$763000.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 246.17% to -$763000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, down 134.21% year-over-year, with the annual reading at -$1.1 million for FY2025, 134.21% down from the prior year.
  • Interest & Investment Income for Q4 2025 was -$763000.0 at Orchestra BioMed Holdings, down from -$515000.0 in the prior quarter.
  • The five-year high for Interest & Investment Income was $1.1 million in Q4 2023, with the low at -$763000.0 in Q4 2025.
  • Average Interest & Investment Income over 3 years is $423100.0, with a median of $712000.0 recorded in 2024.
  • The sharpest move saw Interest & Investment Income grew 0.11% in 2024, then crashed 246.17% in 2025.
  • Over 3 years, Interest & Investment Income stood at $1.1 million in 2023, then plummeted by 52.89% to $522000.0 in 2024, then plummeted by 246.17% to -$763000.0 in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at -$763000.0, -$515000.0, and -$36000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.